These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23663723)

  • 1. [Telaprevir-induced pityriasis rubra pilaris].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 May; 140(5):414-5. PubMed ID: 23663723
    [No Abstract]   [Full Text] [Related]  

  • 2. Telaprevir for the treatment of chronic hepatitis C infection.
    Muir AJ
    Expert Rev Anti Infect Ther; 2011 Dec; 9(12):1105-14. PubMed ID: 22114960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection].
    Macías J; Rivero A
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():33-6. PubMed ID: 24063901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P; Reddy KR
    Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug rash with eosinophilia and systemic symptoms due to telaprevir.
    Montaudié H; Passeron T; Cardot-Leccia N; Sebbag N; Lacour JP
    Dermatology; 2010; 221(4):303-5. PubMed ID: 20798484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Possible telaprevir-induced pancreatitis. A case study].
    Selvi Sabater P; Espuny Miró A; Muñoz Bertrán ED; Plaza Aniorte J
    Farm Hosp; 2013; 37(3):269-70. PubMed ID: 23789806
    [No Abstract]   [Full Text] [Related]  

  • 7. ADVANCE study begins enrollment.
    AIDS Patient Care STDS; 2008 Apr; 22(4):345. PubMed ID: 18422463
    [No Abstract]   [Full Text] [Related]  

  • 8. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A; Serfaty L
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment after short course of telaprevir-based therapy in chronic hepatitis C infected patient.
    Dutilh JC; Arends JE
    Neth J Med; 2013 Sep; 71(7):391-2. PubMed ID: 24038569
    [No Abstract]   [Full Text] [Related]  

  • 10. [New agents for the treatment of hepatitis C].
    Buti M; Homs M
    Enferm Infecc Microbiol Clin; 2012 Mar; 30(3):147-50. PubMed ID: 22118805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Conclusions].
    Pineda JA
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():49-50. PubMed ID: 24063903
    [No Abstract]   [Full Text] [Related]  

  • 12.  Pegylated interferon, but not conventional interferon therapy induced severe skin lesions.
    Li Z; Ji F; Zheng Y; An J; Peng Z
    Ann Hepatol; 2012; 11(4):570-1. PubMed ID: 22700642
    [No Abstract]   [Full Text] [Related]  

  • 13. Adding telaprevir improves cure rate in patient with HCV infection.
    AIDS Patient Care STDS; 2010 Dec; 24(12):807. PubMed ID: 21188771
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cutaneous necrosis due to injection of interferon-alpha 2b in a patient with chronic hepatitis C].
    Castellanos González M; Pérez Carreras M; Muñoz Gómez R; Castellano Tortajada G
    Gastroenterol Hepatol; 2011 Oct; 34(8):584-5. PubMed ID: 21641684
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimal treatment with telaprevir for chronic HCV infection.
    Jesudian AB; Jacobson IM
    Liver Int; 2013 Feb; 33 Suppl 1():3-13. PubMed ID: 23286840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telaprevir phase 3 realize trial starts.
    AIDS Patient Care STDS; 2008 Oct; 22(10):837. PubMed ID: 18847391
    [No Abstract]   [Full Text] [Related]  

  • 17. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug Rash with Eosinophilia and Systemic Symptoms syndrome induced by telaprevir in a patient with chronic hepatitis C virus infection].
    Martín Domínguez V; Carrascosa de Lome R; Becerro González I; de Argila D; Villar K; García-Buey L
    Gastroenterol Hepatol; 2015 Oct; 38(8):491-3. PubMed ID: 25454599
    [No Abstract]   [Full Text] [Related]  

  • 19. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.
    Benhamou Y; Moussalli J; Ratziu V; Lebray P; De Backer K; De Meyer S; Ghys A; Luo D; Picchio GR; Beumont M
    J Infect Dis; 2013 Sep; 208(6):1000-7. PubMed ID: 23801602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C.
    Med Lett Drugs Ther; 2011 Jul; 53(1369):57-9. PubMed ID: 21778964
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.